Disruptive Mood Dysregulation Disorder (DMDD)

Disruptive mood dysregulation disorder (DMDD) is a relatively new diagnostic category introduced in DSM-5 (2013) to address concerns about overdiagnosis of pediatric bipolar disorder in children with severe chronic irritability who did not meet bipolar criteria. DSM-5 criteria require: (1) severe recurrent temper outbursts (verbal rages or behavioral aggression) grossly out of proportion to situation; (2) outbursts inconsistent with developmental level; (3) outbursts occur on average 3 or more times per week; (4) mood between outbursts is persistently irritable or angry most of the day, nearly every day, observable to others; (5) duration ≥12 months, no symptom-free period exceeding 3 months; (6) symptoms in at least 2 of 3 settings (home, school, peers); (7) onset before age 10 with first diagnosis between ages 6 and 18; (8) symptoms not better explained by another disorder.

Epidemiology and pathophysiology: prevalence 2-5% in school-age children, more common in males, often with comorbid ADHD (60-93%), oppositional defiant disorder, anxiety, depression. Considered to share more in common with depressive and anxiety disorders than bipolar disorder based on longitudinal studies. Differential diagnosis is critical: pediatric bipolar disorder (episodic with discrete manic episodes vs DMDD with chronic irritability), oppositional defiant disorder (DMDD diagnosis takes precedence if criteria met for both), intermittent explosive disorder (no requirement for chronic interepisodic irritability), autism spectrum disorder (different developmental presentation), ADHD with severe irritability (treat ADHD first), reactive attachment disorder, anxiety, depression, abuse-related trauma. Risk factors include family history of mood disorders, environmental stressors, neurobiological factors with abnormal frontolimbic connectivity, deficits in emotion regulation, attention dysfunction.

Diagnosis is by structured clinical interview with child and parents, comprehensive psychiatric evaluation, behavioral rating scales (Child Behavior Checklist, Affective Reactivity Index — ARI for irritability), school information, medical evaluation to exclude other causes, longitudinal observation. Treatment: psychosocial interventions are first-line including parent management training (PMT) for emotion coaching, dialectical behavior therapy adapted for adolescents (DBT-A), cognitive-behavioral therapy targeting emotion regulation and irritability, computerized interpretation bias training (some evidence). Pharmacotherapy considered for severe symptoms, comorbidity, or inadequate response to psychotherapy: stimulants (methylphenidate, amphetamines) particularly effective for comorbid ADHD with irritability, alpha-2 agonists (guanfacine, clonidine), atypical antipsychotics (risperidone, aripiprazole — used cautiously due to metabolic side effects), SSRIs (fluoxetine, sertraline) particularly for comorbid depression/anxiety, mood stabilizers (lithium, valproate — limited evidence). Combined treatment usually most effective. Long-term outcomes show DMDD predicts adult depressive and anxiety disorders rather than bipolar disorder, persistent functional impairment if untreated, family interventions essential, school-based supports, regular reassessment of diagnosis as child develops.